HBOC-201, hemoglobin glutamer-250 (bovine), Hemopure® (Biopure Corporation)

Expert Opinion on Biological Therapy

Volumn 8, Issue 9, 2008, Pages 1425-1433

  Jahr, Jonathan S ^a   Moallempour, Mojgan ^a   Lim, Jennifer C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blood substitute; HBOC 201; Hemoglobin based oxygen carrier; Hemopure

Indexed keywords

HBOC 250; HEMEASSIST; HEMOGLOBIN; HEMOGLOBIN GLUTAMER 200; HEMOGLOBIN GLUTAMER 250; HEMOSPAN; HETASTARCH; HRC 101; OXYVITA; POLYMERIZED HEMOGLOBIN; TROPONIN; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ANEMIA; ANGINA PECTORIS; ARTERY THROMBOSIS; ARTICLE; ASTHENIA; BLEEDING; BLOOD PRESSURE; CARDIOPULMONARY BYPASS; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEMATURIA; HUMAN; HYPERTENSION; JAUNDICE; LACTATION; LOADING DRUG DOSE; NAUSEA; NONHUMAN; ORTHOPEDIC SURGERY; OXYGEN TRANSPORT; PEROPERATIVE CARE; POSTMARKETING SURVEILLANCE; POSTOPERATIVE CARE; PREGNANCY; SCLERA DISCOLORATION; SCLERA DISEASE; SIDE EFFECT; SKIN DISCOLORATION; THROMBOCYTE DYSFUNCTION;

BLOOD SUBSTITUTES; CLINICAL TRIALS AS TOPIC; HEMOGLOBINS; HUMANS;

BOVINAE;

EID: 52949142206     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.8.9.1425     Document Type: Article

References (47)

1. Hébert PC, Wells G, Blajchman MA, et al. A multicenter, randomized controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999;340:409-17
2. Hill GE, Frauley WH, Griffith KE, et al. Allogeneic blood transfusion increases the risk of postoperative bacterial infection: a meta-analysis. J Trauma 2003;54:908-14
3. Madjdpour C, Spahn DR. Allogeneic red blood cell transfusion: efficacy, risks, alternatives and indications. Br J Anaesth 2005;95:33-42
4. Jahr JS, Walker V, Manoochehri K. blood substitutes as pharmacotherapies in clinical practice. Curr Opin Anaesthesiol 2007;20:325-30
5. Schubert A, Przybelski RJ, Eidt JF, et al. Diaspirin-crosslinked hemoglobin reduces blood transfusion in noncardiac surgery: a multicenter, randomized, controlled, double-blinded trial. Anesth Analg 2003;97:323-32
6. Gould SA, Moore EE, Hoyt DB, et al. The first randomized trial of human polymerized hemoglobin as a blood substitute in acute trauma and emergent surgery. J Am Coll Surg 1998;187(2):113-20
7. Gould SA, Moore EE, Hoyt DB, et al. The life-sustaining capacity of human polymerized hemoglobin when red cells might be unavailable. J Am Coll Surg 2002;195(4):445-52
8. Jahr JS, Varma N. Polyheme. Northfield laboratories. IDrugs 2004;7(5):478-82
9. Greenburg AG, Kim HW; Hemolink Study Group. Use of an oxygen therapeutic as an adjunct to intraoperative autologous donation to reduce transfusion requirements in patients undergoing coronary artery bypass graft surgery. J Am Coll Surg 2004;198:373-83
10. Northfield Laboratories, Inc. Presentation at FDA/NIH Workshop on Hemoglobin-Based Oxygen Carriers: Available from: http://www.northfieldlabs.com [Last accessed 12 July 2008]
11. Available from: http://securities.stanford.edu/1035/NFLD_01/ [Last accessed 12 July 2008]
12. Hemosol, Biopharma, Inc. Available from: http://pharmalicensing.com/ public/press/view/1187019131_46c0797b631ff/newly-created-hemosol- biopharma-inc-on-the-hunt-for-partnership-licensing-and-acquisition- targets [Last accessed 12 July 2008]
13. Crawford MW, Shichor T, Engelhardt T, et al. The novel hemoglobin-based oxygen carrier HRC101 improves survival in murine sickle cell disease. Anesthesiology 2007;107(2):281-7
14. Matheson B, Kwansa H, Bucci E, et al. Vascular response to infusions of a nonextravasating hemoglobin polymer. J Appl Physiol 2002;93:1479-86
15. Björkholm M, Fagrell B, Przybelski R, et al. A phase I single blind clinical trial of a new oxygen transport agent (MP4), human hemoglobin modified with maleimide-activated polyethylene glycol. Haematologica 2005;90(4):505-15
16. Olofsson C, Ahl T, Johansson T, et al. A multicenter clinical study of the safety and activity of maleimide-polyethylene glycol-modified Hemoglobin (Hemospan) in patients undergoing major orthopedic surgery. Anesthesiology 2006;105(6):1153-63
17. Phase III Study of Hemospan® for treating hypotension in hip arthroplasty has been completed in Europe in April 2008, data has not published yet. Available from: http://clinicaltrials.gov/ct/show/ NCT00420277?order=1 [Last accessed 12 July 2008]
18. A safety study of Hemospan® in total prostatectomy patients has been completed in US in Feb. 2008, data has not published yet. Available from: http://clinicaltrials.gov/ct/show/NCT00425334?order=3 [Last accessed 12 July 2008]
19. Jahr JS, Weeks D, Desai P, et al. Does Oxyvita, a new generation hemoglobin-based oxygen carrier, or Oxyglobin acutely interfere with coagulation compared with normal saline or 6% Hetastarch? An ex vivo thromboelastography preliminary study. J Cardiothorac Vasc Anesth 2008;22(1):34-9
20. OxyVita official website. Available from: http://www.oxyvita.us/ [Last accessed 12 July 2008]
21. Oxyglobin package insert. Available from: http://www.hboclab.com/pdf/ oxyglobinpi.pdf [Last accessed 12 July 2008]
22. Natanson C, Kern SJ, Lurie P, et al. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA 2008;299(19):2304-12
23. Hemopure website. Available from: http://www.biopure.com [Last accessed 12 July 2008]
24. Hemopure package insert information. Available from: http://www.hbodab.com/pdf/HemopurePackageInsert.pdf [Last accessed 12 July 2008]
25. Lowe LC. Blood substitutes: from chemistry to clinic. J Mater Chem 2006;16(43):4189-96.
26. Page TC, Light WR, McKay CB, et al. Oxygen transport by erthrocyte/ hemoglobin solution mixtures in an in vitro capillary as a model of hemoglobin-based oxygen carrier performance. Microvasc Res 1998;55:54-64
27. Lurie F, Jahr JS, Driessen B, et al. The novel HemoCue plasma/low hemoglobin system accurately measures small concentrations of three different hemoglobin-based oxygen carriers in plasma: hemoglobin glutamer-200 (bovine) (Oxyglobin), hemoglobin glutamer 250(bovine) (Hemopure) and hemoglobin-raffimer (Hemolink). Anesth Analg 2002;95(4):870-3
28. Food and Drug Administration presentation to Blood Products Advisory Committee: NMRC RESUS protocol using HBOC-21. December 14, 2006. Available from: http://www.fda.gov/ohrms/dockets/ac/06/slides/ 2006-4270S_4.ppt [Last accessed 12 July 2008]
29. Jahr JS, Mackenzie C, Pearce LB, et al. HBOC-201 as an alternative to blood transfusion: efficacy and safety evaluation in a multicenter Phase III trial in elective orthopedic surgery. J Trauma 2008;64(6):1484-97
30. La Muraglia GM, O'Hara P, Baker WH, et al. The reduction of the allogenic transfusion requirement in aortic surgery with a hemoglobin-based solution. J Vasc Surg 2000;31:299-308
31. Levy JH, Goodnough LT, Greilich PE, et al. Polymerized bovine hemoglobin solution a replacement for allogeneic red blood cell transfusion after cardiac surgery: results of a randomized, double-blind trial. J Thorac Cardiovasc Surg 2002;124(1):35-42
32. Hemoglobin based oxygen therapeutics in elective percutaneous coronary revascularization. Available from: http://clinicaltrials.gov/ct2/show/ NCT00479895 [Last accessed 12 July 2007]
33. A Study of Hemopure® to enhance tissue preservation during cardiopulmonary bypass surgery Available from: http://www.clinicaltrials.gov/ct2/show/NCT00301535?term= polymerized+hemoglobin&rank=4 [Last accessed 12 July 2008]
34. Safety/feasibility study of HBOC-201 in amputation at/below knee from critical lower limb ischemia, [This study was stopped due to slow enrollment and changes in standard of care]. Available from: http://www.clinicaltrials.gov/ct2/show/NCT00300040?term= polymerized+hemoglobin&rank=1 [Last accessed 12 July 2008]
35. A single site safety and tolerability study of HBOC-201 in trauma subjects. Available from: http://www.clinicaltrials.gov/ct2/show/ NCT00301483?term=polymerized+hemoglobin&rank=3 [Last accessed 8 May 2008]
36. Levien LJ. South Africa: clinical experience with Hemopure. ISBT Sci Ser 2006;1:167-73
37. Presentation at NIH/FDA HBOC Workshop; 30 April 2008. Biopure Corporation's presentation by AG Greenburg MD PhD, FACS, VP Medical Affairs, at the HBOC Workshop held at the National Institute of Health in Bethesda, MD. Available from: http://www.biopure.com/fda_workshop.php and Available from http://www.biopure.com/ Biopure_Presentation_HBOC_Workshop_4-08.pdf [Accessed 12 May 2008]
38. Kasper SM, Grune F, Walter M, et al. The effects of increased doses of bovine hemoglobin on hemodynamics and oxygen transport in patients undergoing preoperative hemodilution for elective abdominal aortic surgery. Anesth Analg 1998;87:284-91
39. Sprung J, Kindscher JD, Wahr JA, et al. The use of Bovine Hemoglobin Glutamer-250 (Hemopure®) in surgical patients: results of a muticenter, randomized, single-blinded tial. Anesth Analg 2002;94:799-808
40. Jahr JS, Liu H, Gull A, et al. Does HBOC-201(Hemopure®) affect platelet function in orthopedic surgery: a single site analysis. Anesth Analg 2008;106:S-11
41. Jahr JS, Lurie F, Gosselin R, et al. Effects of hemoglobin glucamer-250(bovine) (HBOC-201, Hemopure) on coagulation testing. Am J Ther 2002;9:431-6
42. James MF, Potgierter HE, Ellis P. The effect of Hemopure® on coagulation in clinically relevant concentrations. Anesth Analg 2004;99:1593-97
43. Osgood SL, Jahr JS, Desai P, et al. Does methemoglobin from oxidized hemoglobin-based oxygen carrier (Hemoglobin glutamer-200) interfere with lactate measurement (YSI 2700 SELECT™ Biochemistry Analyzer). Anesth Analg 2005;100:437-9
44. Ma Z, Monk TG, Goodnough LT, et al. Effect of hemoglobin- and perfluboron-based oxygen carriers on common clinical laboratory tests. Clin Chem 1997;43(9):1732-7
45. Available from http://www.hboclab.com/generalguidance.php# [Last accessed 12 July 2008]
46. Jahr JS, Lurie F, Driessen B, et al. Validation of oxygen saturation measurements in a canine model of hemoglobin-based oxygen carrier infusion. Am J Ther 2003;10(1):21-8
47. Lurie F, Driessen B, Jahr JS, et al. Validity of arterial and mixed venous oxygen saturation measurements in a canine hemorrhage model after resuscitation with varying concentrations of hemoglobin-based oxygen carrier. Anesth Analg 2003;96(1):46-50